You tell me!
LONDON (Reuters) - Shares in British drug maker Shire leapt as much as 10 percent on Friday, as traders reported talk of bid interest from U.S. rival Pfizer.
But some analysts thought a tie-up was unlikely, saying Shire's focus on treatments for attention deficit hyperactivity disorder (ADHD) and enzyme replacement therapies did not fit with Pfizer's drugs portfolio or its pipeline of new medicines.
No comments:
Post a Comment